Zevra Therapeutics to Present at the J.P. Morgan 44th Annual Healthcare Conference
Zevra Therapeutics, Inc. (ZVRA)
Company Research
Source: GlobeNewswire
CELEBRATION, Fla., Jan. 08, 2026 (GLOBE NEWSWIRE) -- Zevra Therapeutics, Inc. (NasdaqGS: ZVRA) (Zevra, or the Company), a commercial-stage company focused on providing therapies for people living with rare disease, today announced that members of Zevra’s executive leadership team will present at the J.P. Morgan 44th Annual Healthcare Conference in San Francisco, CA on Thursday, January 15, 2026, at 9:45 a.m. PT. Additionally, management will be available for one-on-one meetings with registered conference attendees. A link to the live webcast will be accessible on the “Events & Presentations” page in the Investor Relations section of Zevra’s website at investors.zevra.com. About Zevra Therapeutics, Inc. Zevra Therapeutics, Inc. is a purpose-driven, commercial-stage company focused on bringing life-changing therapeutics to people living with rare diseases. The company’s commercialization of its lead product, marketed in the U.S. for Niemann-Pick disease type C (NPC), a rare, progre
Show less
Read more
Impact Snapshot
Event Time:
ZVRA
Last Price
Price Change
Price Change%
Volume Shares
Max Up
Max Down
%
Volume Ratio
Performance Comparison
Updated
|
Event Day
Stock performance from the time of news release until the following 4pm ET market close
|
Last price at news event
|
Since Event
Multi-day stock performance from the time of the news release
|
|---|---|---|
|
EVENT DAY
Stock performance from the time of news release until the following 4pm ET market close
|
LAST
PRICE AT NEWS EVENT |
SINCE EVENT
Multi-day stock performance from the time of the news release
|
| Last Price | ||
| VWAP | ||
|
High:
|
Max Up |
High:
|
|
Low:
|
Max Down |
Low:
|
|
%
|
Post news range |
%
|
|
|
Price change |
|
|
|
Price Change Percentage |
|
|
|
S&P 500 (SPX) |
|
|
%
|
Volume ratio |
%
|
| Volume | ||
| Ticks | ||
|
|
Avg transaction size |
|
Don't Miss Out On The Next BIG Stock Move
Event day
Event Day Chart will not be displayed beyond 90-day period of the event
Performance since event
Time And Velocity Analysis
Be the first to know
Opt in for alerts from News Quantifed
Sign Up Today
Opt-in for
ZVRA alerts
Learn More With NQ
Reading the Impact Report
Help Me Understand This Data
Help Me Understand This Data
How NQ Works
What is news-based trading?
And why is it so successful?
And why is it so successful?
Movers & Shakers
The biggest gainers and losers and WHY it moved
ZVRA alerts
High impacting Zevra Therapeutics, Inc. news events
Weekly update
A roundup of the hottest topics
ZVRA
News
- Zevra Therapeutics (NASDAQ:ZVRA) had its "sell (d+)" rating reaffirmed by analysts at <a style="font-weight:bold" href="https://weissratings.com/">Weiss Ratings</a>.MarketBeat
- Zevra Therapeutics: Asymmetric Risk-Reward Setup In Ultra-Rare Disease Market [Seeking Alpha]Seeking Alpha
- Zevra Therapeutics (NASDAQ:ZVRA) was given a new $26.00 price target on by analysts at HC Wainwright.MarketBeat
- Zevra Therapeutics Executes Distribution Agreement to Broaden Access to MIPLYFFA® for the Treatment of Niemann-Pick Disease Type C (NPC)GlobeNewswire
- Is Zevra Therapeutics Attractively Priced After Recent Rare Disease Pipeline Progress? [Yahoo! Finance]Yahoo! Finance
ZVRA
Earnings
- 11/5/25 - Beat
ZVRA
Sec Filings
- 1/7/26 - Form 4
- 12/17/25 - Form 8-K
- 12/9/25 - Form 4
- ZVRA's page on the SEC website